**DRUG PRIOR AUTHORIZATION COMMITTEE MEETING**
**DECEMBER 17, 2009**
**205 JEFFERSON STREET**
**JEFFERSON CITY, MO 65101**

**Committee Members Present**
Gene Forrester, RPh,
Steven Calloway, RP.
Conrad Balcer, DO
Pat Bryant, PharmD by Teleconference
Morgan Sperry, PharmD, Alternate by Teleconference
Joe Parks, MD

**Committee Members Absent**
Henry Petry, DO

**Contractors Present**
Tom Beetem, Infocrossing
Jennifer Kemp-Cornelius, ACS
Rick Pope, First Health Services
Mark Roaseau, ACS

**MO HealthNet Staff Present**
George L. Oestreich, PharmD, Deputy Division Director
Rhonda Driver, RPh, Director Pharmacy Program
Jay Bryant-Wimp, RPh, Clinical Pharmacist
Beth McQuaide, Special Assistant
Allison Lauf, RN
Andrew Haslag, Fiscal Manager
Tisha McGowan, Unit Supervisor
D.J. Johnson, Program Development Specialist
Debbie Bradley, Medicaid Specialist
Angela Wilson, Unit Supervisor
Jenna Twehus, RN
Michelle Overman, Pharmacy Technician
Mary Heet, RN

**Others Attending**
Joey Erickson, Lilly
Phil King, Pfizer
Richard Mesquias, Lilly
Lon Lowrey, Novartis
John Valenti, Sanofi Aventis
Nicole Grisgold, Shire
Bob Gustafoson, Lundbeck
Ronnie DePue, Forest
Scot Green, Pfizer
Grant Cale, BMS
John O'Mally, Genzyme
Rob Kilo, Pfizer
Susan Zalenski, J&J
Jim Graham, OMJ
Ron Schnare, Shire
Gary Detmer, Taro
Naomi Musage, Strativa
Todd Houldsworth, OMJ
Rick Vissing, Pfizer
Bryan Goeckner, BMI
Erin Luebbering, B&D
Brad Brinrey, Actelion
Steve Whiten, Taro
P Wingbermur, Astra Zeneca
Dennise Jacbobsen, Sanofi Aventis
Ashley Nixon-Mongles, Student
Don Larsen, Forest
Travis Cloud, BI
Paige Nardi, King
Eric Gardner, Pfizer
Mirha Nazao, Actelion
Brian Macomson, J&J
Annie Palmer, Taro
Jeff Knappen, Allergan
Ani Nathalaney,
John Harris, Abbott
Bob Bolinger, Forest
Eric Blake, Merck
Charles Martin, KORS

| | |
|---|---|
| **Welcome, Introductions and Opening Remarks** | In the absence of Chairman Henry Petry, D.O.,the meeting was called to order at approximately 10:30 a.m. by George L. Oestreich, Pharm.D., Deputy Division Director for the MO HealthNet Division (MHD). |
| **Minutes Approval** | Minutes for the meeting held September 18, 2008 were reviewed and approved as submitted. |
| **Pharmacy Program/Budget Update** | Dr. Oestreich presented a PowerPoint presentation entitled *MO HealthNet Issues Update.* Slides presented discussed expected outcomes from various program interventions; outcomes reporting; Chronic Care Improvement Program (CCIP) enrollment; the typical participant and top ten diagnoses by cost. The presentation continued with a discussion of targeted measures and the role of current electronic tools. Dr. Oestreich detailed the programs' successes including improved clinical outcomes, decreases in costs, enhanced electronic health record capabilities, and increased personal responsibility. Dr. Oestreich noted the hospital certification program was underway with home health services certifications scheduled for implementation next. The integration of managed care pharmacy into the fee for service program has gone well, however the call center has seen a dramatic increase in ADHD authorizations. Dr. Oestreich informed the group that the Lewin Group had completed its report on the review of the Pharmacy program. The report is available for review on the Division's Web page under the Oversight Committee heading. He concluded the presentation by updating the group on the statewide health information exchange project underway. Dr. Oestreich responded to questions from the group regarding the MoRx Plan and the potential to place a hold on enrollment. More cost information may be shared at the next meeting as the Governor's recommendations will be released by that date. Copies of slides used are available upon request and will be available on the MO HealthNet Division (MHD) Web page. |
| **DUR Report** | Rhonda Driver, R.Ph., Director of the Pharmacy Program reported the DUR Board had met in October to review the recommendations made by the Drug Prior Authorization (PA) Committee at their September meeting. The Board concurred with all recommendations made by the PA Committee. Ms. Driver noted that the Governor's Office was processing applications for appointments to the Board. |
| **Old Business** | |
| **Tripans PDL Edit** | ●Discussion-A copy of the clinical edit document was provided in the meeting packet and all attendees. Changes under recommendation were bolded for easy identification. Ms. Driver reviewed the document noting the compliance model for the class was now defined as therapy 15 days out of the most recent 60 days. This change had been discussed and recommended at the previous meeting of the Committee.<br>●Public Hearing-No Comments were entered.<br>●Decision- The Committee voted to accept the recommendation as presented. (See Roll Call Votes) |

| | |
|---|---|
| **Megace ES** | A copy of the clinical edit document was provided in the meeting packet and all attendees. Ms. Driver explained at the request of the manufacturer of the product Megace ES a review of the existing Megestrol Acetate Clinical Edit was conducted. MHD was recommending the addition of Megace ES, currently under prior authorization, to the current Megestrol Acetate clinical edit.<br>●Public Hearing-Diane Ranicot, Strativa Pharmaceuticals addressed the Committee requesting Megace ES be removed from the clinical edit. She discussed the differences between Megace ES and Megace. Dr, Ranicot stated benefits of Megace ES included improved bio-availability in unfed patients, lower volume dose, and a viscosity of 94% less than the original formulation Megace. Dr. Ranicot noted an error under denial criteria in the document. The document will be corrected to indicate recommend dose to not exceed 800 mg per day for the product. Dr. Ranicot indicated the product was only meant to be used for at 90 day period.<br>●Decision- After Committee discussion the vote was tabled to allow for review of duration of therapy data. |
| **Implementation Schedule** | An updated copy of the Proposed Implementation Schedule for Edits was included in the member's meeting packet and as a handout to all attendees. The schedule had been updated with all edits approved at the last quarter's meeting. This included the implementation following the annual review of half of the PDL done in September and October. The schedule may be found on the MHD Web-site at http://dss.missouri.gov/mhd/cs/pharmacy/imsched.pdf. |
| **New Business** | |
| **New Drug Review** | ● Discussion - Drug Monographs were available for review at http://www.heritage-info.com/mohealthnet/ for all new products reviewed this quarter. A listing of products detailing MHD's recommendations for open access, clinical edit, as a PDL product or for continued prior authorization was provided in the Members' meeting packets for discussion and action. This listing was also provided as a handout to all in attendance. Ms. Driver reviewed the recommendations and responded to Committee questions.<br>● Public Hearing – Bryan Goeckner, with Bristol Meyer Squibb spoke in support of the product Onglyza. Dr, Goeckner provided and summarized a handout on the product, Efficacy, safety, side effects, drug interaction, convenience of dosing and outcomes were detailed in the handout. Chuck Marsh addressed the Committee on behalf of King Pharmaceuticals and in support of the product Embeda. Dr, Marsh summarized the mechanism of action, safety, efficacy and studies surrounding the product.<br>● Decision – Following this discussion the Committee voted to accept the new drug recommendations as presented. (See Roll Call Votes) |
| **PDL Edits** | |
| **PDL Edits**<br>**Fibromyalgia Agents** | ● Discussion – Ms. Driver reviewed the criteria document provided as a meeting handout. Preferred and Non Preferred agents as well as existing clinical edits that will continue as the |

| | |
|---|---|
| | products are rolled into the PDL were summarized.<br>● Public Hearing – Phil King, Pfizer Pharmaceuticals requested the Committee consider the product Lyrica be move to preferred status. Dr. King discussed the differences of the product, clinical studies, safety, and efficacy of the product.<br>● Decision – The Committee voted to accept the recommendation as presented. (See Roll Call Votes) |
| **PDL Edits**<br>**Cryopyrin-Associated Periodic Syndrome (CAPS) Agents** | ● Discussion – Mr. Bryant-Wimp reviewed the criteria document, noting preferred and non-preferred agents and approval/denial criteria.<br>● Public Hearing – No comments were entered.<br>● Decision – The Committee voted to accept the recommendation as presented. (See Roll Call Votes) |
| **PDL Edits**<br>**Self-Injectable Epinephrine Agents** | ● Discussion – Ms. Driver reviewed the criteria document provided as a meeting handout noting MHD recommendations for preferred and non-preferred agents. Questions from the Committee surrounding the non preferred agent were answered.<br>● Public Hearing – No comments were entered.<br>● Decision – The Committee voted to accept the recommendation as presented. (See Roll Call Votes) |
| **PDL Edits**<br>**Tramdol Like Agents** | ● Discussion – Mr. Bryant-Wimp reviewed the criteria document noting recommendations for preferred and non-preferred agents. Approval and denial criteria were reviewed as well. Discussion ensued surrounding serotonin syndrome. The Committee concurred that this would be an excellent topic for a DUR newsletter.<br>● Public Hearing – Brian Macomson, Johnson and Johnson discussed the product Nucynta and requested preferred status be considered. The differences of the product, clinical trials, safety and efficacy data were presented,<br>● Decision –The Committee voted to accept the recommendation as presented. (See Roll Call Votes) |
| **PDL Edits**<br>**Pulmonary Hypertension Agents** | ● Discussion – Mr. Bryant-Wimp reviewed the criteria document noting recommendations for preferred and non-preferred agents. A clarification that this edit was for inhaled and inject-able agents (Oral agents are already part of the PDL) was given by Ms. Driver. She indicated the two dosing forms would be merged into one edit in the future.<br>● Public Hearing – No comments were entered.<br>● Decision –The Committee voted to accept the recommendation as presented, however wish to review utilization data as warranted.. (See Roll Call Votes) |
| **Preferred Drug List Announcement** | A handout of therapeutic categories for the annual review of half of the PDL during the next quarter was included in the meeting packet and to all meeting attendees. This listing will be posted to the Division's web page at http://www.dss.mo.gov.mhd. The posting will be updated |

| | |
|---|---|
| | with MHD recommendations prior to the March meeting of the Committee. |
| **Program Utilization Information** | A listing of the top 25 drugs for dates of services for the 4th quarter 2009 was provided for the Committees' Information. This report was provided in two formats: ranked by number of claims and ranked by amount paid. Copies were available to all attendees. |
| **Clinical Edit Summary Report** | An overview of clinical edit and prior authorization transactions was provided for the entire year (2009). The report provided total transaction counts as well as information on the outcome (approval or denial) of the requests. CyberAccess active count reports for the month of November with also provided for the Committees information and review. |
| **Call Center Statistics** | A handout detailing pharmacy help desk call center activity was provided for all attending. Statistics the year, 2009 was provided for review. |
| **Adjourn** | The next meeting of the Committee is scheduled for **March 18, 2010.** The Drug PA Committee went into executive session for the sole purpose of discussing individual participant specific medical information. At the conclusion of these discussions the group adjourned entertaining no further business, actions or motions. (See Roll Call Votes) |

**DECEMBER 17, 2009 ROLL CALL VOTES**

| Member | Attendance | Triptans | Megace ES | New Drug Review | Onglyza | Embeda | Fibromyalgia | Epinephrine | CAPS Agents | Tramdol Like |
|---|---|---|---|---|---|---|---|---|---|---|
| **HENRY PETREE** | ABSENT | ABSENT | ABSENT | ABSENT | ABSENT | ABSENT | ABSENT | ABSENT | ABSENT | ABSENT |
| **GENE FORRESTER** | PRESENT | **SECOND** | **SECOND** | YEAH | **MOTION** | **SECOND** | **MOTION** | YEAH | YEAH | YEAH |
| **STEVE CALLOWAY** | PRESENT | YEAH | YEAH | **SECOND** | **YEAH** | YEAH | **SECOND** | **SECOND** | **MOTON** | **MOTION** |
| **PAT BRYANT** | PRESENT | YEAH | YEAH | YEAH | **YEAH** | YEAH | YEAH | YEAH | YEAH | YEAH |
| **CONRAD BALCER** | PRESENT | **MOTION** | **MOTION** | **MOTION** | **SECOND** | **MOTION** | YEAH | **MOTION** | **SECOND** | **SECOND** |
| **JOE PARKS** | PRESENT | YEAH | YEAH | YEAH | YEAH | YEAH | YEAH | YEAH | YEAH | YEAH |
| **Morgan Sperry** | PRESENT | | | | | | | | | |

| Member | PHA | Closed Session | Adjourn |
|---|---|---|---|
| **HENRY PETREE** | ABSENT | ABSENT | ABSENT |
| **GENE FORRESTER** | **SECOND** | YEAH | YEAH |
| **STEVE CALLOWAY** | YEAH | **MOTION** | YEAH |
| **PAT BRYANT** | YEAH | YEAH | **MOTION** |
| **CONRAD BALCER** | **MOTION** | **SECOND** | YEAH |
| **JOE PARKS** | YEAH | YEAH | **SECOND** |
| **Morgan Sperry** | | | |

**EXECUTIVE SESSION**
**December 17, 2009**

**Committee Members Present**
Gene Forrester, R.Ph,
Steven Calloway, R.Ph.
Conrad Balcer, D.O.
Joe Parks, M.D.

**Committee Members Absent**
Henry Petry, D.O.
.

**MO HealthNet Staff Present**
George L. Oestreich, Pharm.D., Deputy Division Director
Rhonda Driver, R.Ph., Director Pharmacy Program
Jay Bryant-Wimp, Clinical Pharmacist
Beth McQuaide, Special Assistant
Tisha McGowan, Unit Supervisor
Mary Heet, RN
Allison Lauf, R.N.
Jenna Twehus, R.N.

**Contractors Present**
Rick Pope, First Health Services
Jennifer Cornelius-Kemp, ACS
Mark Roaseau, ACS

| | |
|---|---|
| **MINUTES REVIEW** | Minutes of the September 2009 Executive Session were approved as submitted. |
| **CASE REVIEWS** | No cases were presented for review. |
| **ADJOURN** | The meeting adjourned at approximately 1:30 p.m. (See Roll Call Votes) |